Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

NCT00341328 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

300

Enrollment

OTHER_GOV

Sponsor class

Conditions

Tuberculosis

Interventions

BIOLOGICAL: Intradermal injection of Mycobacterium w

Sponsor

Ministry of Science and Technology, India